Aims: To evaluate the efficacy and safety of the PROMETA™ Protocol for treating methamphetamine dependence.
Design: A double-blind, placebo-controlled 108-day study with random assignment to one of two study conditions: active medication with flumazenil (2 mg infusions on days 1, 2, 3, 22, 23), gabapentin (1200 mg to day 40) and hydroxazine (50 mg to day 10) versus placebo medication (with active hydroxazine only).
Setting: Three substance abuse treatment clinics: two in-patient, one out-patient.
Participants: Treatment-seeking, methamphetamine-dependent adults (n = 120).
Measurements: Primary outcome was percentage of urine samples testing negative for methamphetamine during the trial.
Findings: No statistically significant between-group differences were detected in urine drug test results, craving, treatment retention or adverse events.
Conclusions: The PROMETA protocol, consisting of flumazenil, gabapentin and hydroxyzine, appears to be no more effective than placebo in reducing methamphetamine use, retaining patients in treatment or reducing methamphetamine craving.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122522 | PMC |
| http://dx.doi.org/10.1111/j.1360-0443.2011.03619.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Musculoskeletal and body composition response to high-dose testosterone with finasteride after chronic incomplete spinal cord injury-a randomized, double-blind, and placebo-controlled pilot study.
Front Neurol
December 2024
Brain Rehabilitation Research Center, Malcom Randall Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, FL, United States.
Article Synopsis
- High-dose testosterone replacement therapy (TRT) combined with finasteride offers benefits such as improved body composition, muscle strength, and bone density in older men, while mitigating the risk of prostate enlargement.
- A pilot study involved 12 men with spinal cord injuries, demonstrating that TRT with finasteride significantly increased lean body mass and muscle size, alongside enhancing bone mineral density compared to a placebo.
- Results suggest TRT + finasteride reduced fat mass and improved muscular strength, with measurable benefits observed as early as 6 months into the treatment, indicating its potential effectiveness for men with low testosterone post-injury.
Background: In the primary analysis of a Phase 3b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis affecting the scalp (NCT03897088), tildrakizumab, an anti-interleukin-23 p19 antibody, met the primary efficacy endpoint at Week (W)16.
Objective: To evaluate maintenance of tildrakizumab efficacy and safety for the treatment of scalp psoriasis from the W52 full analysis.
Methods: Patients randomized to tildrakizumab continued receiving tildrakizumab 100 mg every 12 weeks; patients randomized to placebo (analyzed separately) switched to tildrakizumab 100 mg at W16.
Zoledronic acid as adjuvant therapy in neovascular age-related macular degeneration: a randomised controlled pilot study.
BMJ Open Ophthalmol
December 2024
Department of Ophthalmology, Oslo University Hospital, Oslo, Norway.
Aims: To assess the feasibility of a study protocol for a randomised controlled trial of zoledronic acid (ZA) as adjuvant therapy for neovascular age-related macular degeneration (nAMD).
Methods: In this 1-year, randomised, double-blinded, placebo-controlled pilot study, nAMD patients were allocated 1:1 to receive intravenous ZA 5 mg or placebo at baseline and after 6 months in addition to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy following a treat-and-extend regimen. Bevacizumab was the first-line anti-VEGF drug, but eyes with refractory nAMD were switched to aflibercept.
Timing of intravenous dexamethasone and analgesia after brachial plexus block: a randomized, double-blind, placebo-controlled trial.
Reg Anesth Pain Med
December 2024
Anesthesia and Pain Management, Toronto Western Hospital, Toronto, Ontario, Canada
Background: The addition of intravenous dexamethasone can significantly prolong analgesia and reduce opioid-related side effects after brachial plexus blockade, but the most effective administration time is yet unknown. The objective of this study is to determine if the timing of administration of dexamethasone affects the duration of analgesia after supraclavicular brachial plexus block.
Methods: This is a double-blind, placebo-controlled, randomized trial performed at a single-center, tertiary academic health sciences center.
Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities.
Med Cannabis Cannabinoids
November 2024
Faculty of Nursing, Khon Kaen University, Khon Kaen, Thailand.
Introduction: Diabetic peripheral neuropathy (DPN) represents a prevalent neurological complication affecting millions of patients globally. This clinical investigation evaluated the therapeutic efficacy and safety profile of a novel transdermal medical cannabis formulation (THC:CBD:CBN) in treating painful DPN of the lower extremities.
Methods: This phase III, double-blind, placebo-controlled, randomized clinical trial was conducted at Don Chan Hospital, Thailand, enrolling 100 participants over a 12-week intervention period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!